Susoctocog alfa

Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.^[6][5][7]

Susoctocog alfa

Clinical data
Trade names	Obizur
Other names	Antihemophilic factor (recombinant)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Obizur
Pregnancy category	AU: B2[1]
Drug class	Antihemophilic factor
ATC code	B02BD14 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[2] CA: ℞-only[3] UK: POM (Prescription only)[4] US: ℞-only[5] EU: Rx-only[6] In general: ℞ (Prescription only)
Identifiers
CAS Number	1339940-90-7
DrugBank	DB11606
UNII	6892UQT2GK
KEGG	D10831

Susoctocog alfa was approved for medical use in the United States in October 2014,^[8][9] and for medical use in the European Union in November 2015.^[6]

Factor VIII is one of the proteins needed for normal clotting of the blood.^[6]